Our top pick for
Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 111 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.67|
|52-week range||$4.14 - $8.30|
|50-day moving average||$4.91|
|200-day moving average||$4.99|
|Wall St. target price||$9.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-3.31%|
|1 month (2021-09-24)||-5.66%|
|3 months (2021-07-26)||-4.89%|
|6 months (2021-04-26)||-7.71%|
|1 year (2020-10-26)||-5.08%|
|2 years (2019-10-25)||31.92%|
|3 years (2018-10-26)||5.95|
|5 years (2016-10-26)||1,128.95%|
|Revenue TTM||$24 million|
|Gross profit TTM||$7.7 million|
|Return on assets TTM||-40.97%|
|Return on equity TTM||-91.33%|
|Market capitalisation||$113.4 million|
TTM: trailing 12 months
There are currently 413,554 Orgenesis shares held short by investors – that's known as Orgenesis's "short interest". This figure is 27.9% down from 573,793 last month.
There are a few different ways that this level of interest in shorting Orgenesis shares can be evaluated.
Orgenesis's "short interest ratio" (SIR) is the quantity of Orgenesis shares currently shorted divided by the average quantity of Orgenesis shares traded daily (recently around 41108.747514911). Orgenesis's SIR currently stands at 10.06. In other words for every 100,000 Orgenesis shares traded daily on the market, roughly 10060 shares are currently held short.
However Orgenesis's short interest can also be evaluated against the total number of Orgenesis shares, or, against the total number of tradable Orgenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orgenesis's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Orgenesis shares in existence, roughly 20 shares are currently held short) or 0.0178% of the tradable shares (for every 100,000 tradable Orgenesis shares, roughly 18 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Orgenesis.
Find out more about how you can short Orgenesis stock.
We're not expecting Orgenesis to pay a dividend over the next 12 months.
Orgenesis's shares were split on a 1:12 basis on 15 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.
Over the last 12 months, Orgenesis's shares have ranged in value from as little as $4.14 up to $8.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.2175. This would suggest that Orgenesis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Orgenesis Inc. , a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.